
Quarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited EPS Ratio 2011-2026 | VNRX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -0.45 | -0.41 | -0.57 | -0.56 | -0.52 | -0.54 | -0.61 | -0.34 | -0.44 | -0.45 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.34 | -0.61 | -0.489 |
Quarterly EPS Ratio VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.1 | -0.12 | - | -0.09 | -0.12 | -0.14 | - | -0.1 | -0.11 | -0.12 | - | -0.14 | -0.15 | -0.17 | - | -0.15 | -0.13 | -0.13 | - | -0.15 | -0.13 | -0.13 | - | -0.16 | -0.1 | -0.12 | - | -0.44 | 0.06 | -0.18 | - | -0.08 | -0.1 | -0.09 | - | -0.09 | -0.1 | -0.09 | - | -0.12 | -0.13 | -0.08 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.06 | -0.44 | -0.125 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Interpace Biosciences
IDXG
|
1.42 | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
-7.69 | $ 123.79 | -0.43 % | $ 19.7 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.13 | -2.74 % | $ 4.89 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 25.75 | 3.0 % | $ 715 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
-0.84 | $ 8.1 | 1.76 % | $ 1.04 B | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | $ 104.91 | - | $ 19.8 B | ||
|
National Research Corporation
NRC
|
50 | $ 17.51 | 1.1 % | $ 392 M | ||
|
Natera
NTRA
|
-5.57 | $ 200.09 | 2.46 % | $ 19.7 B | ||
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
OPKO Health
OPK
|
0.02 | $ 1.15 | 2.68 % | $ 798 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Personalis
PSNL
|
-1.37 | $ 7.61 | 4.82 % | $ 451 M | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 158.0 | 2.86 % | $ 7.83 B | ||
|
IQVIA Holdings
IQV
|
7.91 | $ 166.96 | 0.54 % | $ 28.7 B | ||
|
Lantheus Holdings
LNTH
|
3.46 | $ 75.73 | -0.92 % | $ 5.11 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
IDEXX Laboratories
IDXX
|
13.2 | $ 578.51 | 0.22 % | $ 46.5 B | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.46 | 26.96 % | $ 1.86 M | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 456.93 | 0.98 % | $ 13.2 B | ||
|
Senseonics Holdings
SENS
|
-1.66 | $ 6.62 | 2.16 % | $ 276 M | ||
|
Sotera Health Company
SHC
|
0.27 | $ 13.88 | 2.81 % | $ 3.94 B | ||
|
Agilent Technologies
A
|
3.98 | $ 112.02 | 0.65 % | $ 34.1 B | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 100.35 | 0.65 % | $ 8.28 B | ||
|
Soleno Therapeutics
SLNO
|
0.4 | $ 31.72 | -4.52 % | $ 1.61 B | ||
|
DarioHealth Corp.
DRIO
|
10.1 | $ 7.5 | -6.13 % | $ 29.9 M | ||
|
Guardant Health
GH
|
-3.32 | $ 84.9 | -0.33 % | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
-3.95 | $ 4.66 | 1.75 % | $ 432 M | ||
|
Psychemedics Corporation
PMD
|
-0.72 | - | -1.84 % | $ 15.3 M | ||
|
Neuronetics
STIM
|
-0.59 | $ 1.6 | 10.34 % | $ 106 M | ||
|
QIAGEN N.V.
QGEN
|
0.38 | - | - | $ 10.6 B | ||
|
Mettler-Toledo International
MTD
|
42.2 | $ 1 239.07 | 2.87 % | $ 25.5 B | ||
|
CareDx, Inc
CDNA
|
-0.4 | $ 17.56 | 2.39 % | $ 936 M | ||
|
ENDRA Life Sciences
NDRA
|
-5.55 | $ 3.48 | 0.87 % | $ 1.87 M | ||
|
Thermo Fisher Scientific
TMO
|
17.8 | $ 478.12 | 0.79 % | $ 180 B | ||
|
Celcuity
CELC
|
-2.83 | $ 106.75 | 0.67 % | $ 4.21 B | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 264.42 | 0.54 % | $ 22 B |